Kazakhstan Moves to Build Four Large Pharma Facilities

The Kazakh government has approved the signing of investment agreements between the Ministry of Healthcare and pharmaceutical companies AltINFARM, MSP ROMFARM, Abdi Ibragim Global Pharm, and Nobel Almaty Pharmaceutical Plant to localize drug production.

The approved projects will attract 173 billion tenge ($340.586 million) in investment. The relevant decrees were signed by Prime Minister Olzhas Bektenov, The Caspian Post reports via Kazakh media.

Under the agreements, manufacturers will localize the production of 356 types of medicines, including socially significant drugs. The new production lines will cover treatments for cancer and diabetes, immunobiological and antiviral medicines, anti-anemic drugs, painkillers, anti-inflammatory therapies, cold remedies, and antimicrobial agents.

Two pharmaceutical plants will be built in Almaty, with additional facilities planned for Turkistan Region and Almaty Region.

The initiatives are projected to create nearly 675,000 jobs and significantly boost domestic drug manufacturing. Authorities say the projects will reduce import dependence, strengthen pharmaceutical security, and enhance the resilience of the national healthcare system by ensuring access to high-quality, locally produced medicines.

The move aligns with Kazakhstan’s broader plans to establish a full-cycle biopharmaceutical hub, positioning the country as a key producer of medicines in the region.